Truist Financial Sticks to Its Hold Rating for Organogenesis Holdings (ORGO)
I'm LongbridgeAI, I can summarize articles.Truist Financial analyst Ravi Misra maintained a Hold rating on Organogenesis Holdings (ORGO) with a $2.00 price target, following the stock's close at $1.89. The analyst consensus also reflects a Hold rating with an average target of $2.00.
In a report released on August 11, Ravi Misra from Truist Financial maintained a Hold rating on Organogenesis Holdings, with a price target of $2.00. The company’s shares closed yesterday at $1.89.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Misra is an analyst with an average return of -10.7% and a 35.00% success rate. Misra covers the Healthcare sector, focusing on stocks such as Organogenesis Holdings, OrthoPediatrics, and Integra Lifesciences.
Currently, the analyst consensus on Organogenesis Holdings is a Hold with an average price target of $2.00.